CNTN — Canton Strategic Holdings Share News
0.000.00%
Last trade - 00:00- $233.85m
- $192.31m
Brief: Tharimmune, Inc. Closes $545 Million Private Placement To Establish Canton Coin Treasury Strategy
Brief: Tharimmune Inc Enters $5.35 Mln Securities Purchase Agreement - SEC Filing
Brief: Don Kim Resigns as CFO of Tharimmune effective immediately - SEC filing
Brief: Tharimmune - Randy Milby Resigns As CEO And Board Member
Brief: Tharimmune Inc - Appoints Vincent Lopriore As Executive Chairman - SEC Filing
Brief: Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology
Brief: Tharimmune Says Thomas Hess Resigns As CFO
Brief: Tharimmune Inc Announces $2.02 Million Private Placement To Advance Development Programs
Brief: Tharimmune Inc Increases Board Size To Six
Brief: Tharimmune Acquires Global License & Partners With Intract Pharma To Develop Oral Formulation Of Infliximab
Brief: Tharimmune Files Prospectus For Offering Of Up To 1 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Tharimmune Received Notice From Nasdaq That Co Has Regained Compliance With Minimum Bid Price Requirement
Tharimmune Inc expected to post a share - Earnings Preview
Brief: Tharimmune Announces Option Agreement For Key Technologies For Generating HER2/HER3 Antibody Drug Conjugates
Brief: Tharimmune Inc - As A Result Of Closing Of The Offering, Co's Total Stockholder Equity Is Now In Excess Of $2.5 Million
Brief: Tharimmune Says On Nov 10, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Tharimmune Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Hillstream Enters Exclusive Option Agreement To Buy Clinical Stage Asset For Chronic Pruritis
Brief: Hillstream Advances Next-Gen Multispecific Antibodies For Solid Tumors